EGFR and non-small cell lung carcinoma: Therefore, exploring the effects of EGFR-TKIs and immunotherapy on metabolic pathways in NSCLC would be useful to elucidate the mechanism of these two new therapies and provide strong evidence for clinical treatment selection from the perspective of metabolism.